{"keywords": [{"value": "Spark Therapeutics Inc.", "rank": "1", "is_major": "Y", "name": "organizations"}, {"value": "Genetics and Heredity", "rank": "2", "is_major": "Y", "name": "subject"}, {"value": "Eyes and Eyesight", "rank": "3", "is_major": "Y", "name": "subject"}, {"value": "Genetic Engineering", "rank": "4", "is_major": "N", "name": "subject"}], "headline": {"print_headline": "Eye Treatment Closes In on Being First Gene Therapy Approved in U.S. ", "main": "Eye Treatment Closes In on Being First Gene Therapy Approved in U.S. "}, "byline": {"contributor": "", "original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "POLLACK", "firstname": "Andrew"}]}, "web_url": "http://www.nytimes.com/2015/10/05/science/eye-treatment-closes-in-on-being-first-gene-therapy-approved-in-us.html", "source": "The New York Times", "subsection_name": null, "slideshow_credits": null, "type_of_material": "News", "_id": "5611f5c738f0d86550b9661c", "multimedia": [], "pub_date": "2015-10-05T00:00:00Z", "print_page": "3", "section_name": "Science", "word_count": "1035", "blog": [], "news_desk": "Business", "snippet": "Spark Therapeutics said the treatment had allowed people with certain so-called inherited retinal dystrophies to maneuver in dimmer light than they could before.", "document_type": "article", "abstract": "Spark Therapeutics announces success in late-stage test for medication used in treating inherited eye disease of retina that can cause blindness; is seeking to become first gene therapy to win approval from Food and Drug Administration. ", "lead_paragraph": "Spark Therapeutics said the treatment had allowed people with certain so-called inherited retinal dystrophies to maneuver in dimmer light than they could before."}